Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE

J. Fayette; C. Cropet; C. Toullec; M. Burgy; A. Bruyas; C. Sire; A. Lagrange; F. Clatot; M. Vinches; M. Iacob; L. M. Garcia Martin; M.-C. Kaminsky; D. Vansteene; S. Salas; A. Champagnac; P. Saintigny; J. Gautier; D. Pérol; J. Bourhis

doi:10.1016/j.esmoop.2026.106946

April 1, 2026ESMO OpenOpen Access

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of durvalumab combined with carboplatin and paclitaxel as a first-line treatment in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) unable to receive cisplatin-based therapies.
Multicenter prospective study design
Target population included frail patients with ECOG-PS of 0-1 and 2
Intervention with durvalumab and weekly carboplatin/paclitaxel
Promising results observed in frail patients
Encouraging response rates in treated cohort
Supports need for further investigation in phase III clinical trials

Implication

Multicenter prospective study shows efficacy of durvalumab with chemotherapy in frail patients with HNSCC, suggesting further trials are needed.

Abstract

The promising results in frail patients with an ECOG-PS of 0-1 and 2 encourages further investigation of durvalumab with weekly carboplatin/paclitaxel in first-line R/M HNSCC patients in a comparative phase III clinical trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fayette et al. (2026) studied this question.

synapsesocial.com/papers/69dc874a3afacbeac03e9c62 https://doi.org/10.1016/j.esmoop.2026.106946

View Full Paper

Ask AI

Bookmark

Share

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE

Key Points

Implication

Abstract

Discussion

Cite This Study

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from ESMO Open

Keep reading

More related papers

More from ESMO Open